IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency” at the following upcoming scientific meetings.
PittGene Meeting
Date: Wednesday, October 25, 2023, at 2:00-2:45pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD
Translational Research in Mitochondria, Metabolism, Aging and Disease (TRiMAD) Meeting 2023
Date: Monday, November 6, 2023, at 5:30-7:00pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD
In this presentation, Reneo and collaborators will report findings which demonstrate that the bioenergetic deficiencies and mitochondrial dysfunction observed in CI-deficient patient fibroblasts can potentially be alleviated by treatment with mavodelpar, a potent and selective PPARδ agonist. Furthermore, because mavodelpar activation results in increased transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation and energy production in the form of ATP, these results provide mechanistic evidence for the potential of mavodelpar as a therapeutic option in this and similar types of primary mitochondrial myopathies (PMM).
Mavodelpar is an investigational drug product candidate that is under clinical investigation, and which has not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, or any other regulatory agency.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com
Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
matthew.purcell@russopartnersllc.com
- Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease - June 16, 2025
- WISeKey Appoints Rolf Gobet to its Strategic Advisory Committee - June 16, 2025
- Jack L. Marcus, Inc. Issues Notice of Privacy Breach Affecting Wisconsin Department of Corrections Population - June 15, 2025
